Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02763319 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 453
- Enrollment target
NCT02763319: Completed Phase 2 study, sponsored by Incyte Corporation.
NCT02763319 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 453 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (241% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02763319, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 453 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Primary Outcome
Progression-free survival was defined as the time from randomization to tumor progression or death from any cause.
Interventions
- DRUG Tafasitamab
- DRUG Rituximab (RTX)
- DRUG Bendamustine (BEN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 2 |
What the finished NCT02763319 record still lists
NCT02763319 is an interventional study that assigns participants to a tested intervention. The registered 453 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (241% higher).
The record links to 0 conditions, and to 3 interventions - of which Tafasitamab is the first listed.
NCT02763319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02763319 about?
NCT02763319 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
What is the current status of trial NCT02763319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 453 participants. The study started on 2016-11-28. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT02763319?
The interventions under investigation include: Tafasitamab (DRUG), Rituximab (RTX) (DRUG), Bendamustine (BEN) (DRUG).
Who is sponsoring clinical trial NCT02763319?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02763319's enrollment target sits among peer trials
453 87th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
- NCT05489211 · 454 participants · Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- NCT05655936 · 454 participants · NA
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI